The U.S. Food and Drug Administration has approved three manufacturing (CMC) supplement submissions—numbers 13, 15 and 18—associated with the ANDA080132 application for Isoniazid. All three supplements received approval status (AP) on dates ranging from March 4, 1982 to January 9, 1985.
The ANDA lists two oral tablet products under the brand name ISONIAZID, identified by product numbers 003 and 004. Product 003 is a 50 mg tablet and product 004 is a 100 mg tablet. Both entries are marked as discontinued in the FDA database.
The sponsor for this application is Purepac Pharm, which submitted the manufacturing supplements to maintain or modify the CMC aspects of the generic Isoniazid products.
Regulatory UpdatesSep 25, 2026•1 min read
FDA Approves Manufacturing Supplements for Isoniazid (ANDA080132)
FDA approved three manufacturing supplement submissions for Isoniazid tablets (50 mg and 100 mg) under ANDA080132; both products are listed as discontinued.
Compiled by the PharmaCountry team · Source: FDA.gov
Ratings
(0)
(0)
(0)
(0)
(0)
More articles
View all insightsResearch & Reports
Global Finished Dosage Manufacturing Landscape 2026
Oct 5, 2026
Regulatory UpdatesKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
Sep 28, 2026
AnalysisPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
Sep 28, 2026
Leave your rating